Oncology Drug Development Update - Monotherapy Phase I Clinical Trials
Posted on: Tuesday, 7 February 2006, 12:00 CST
LAKE FOREST, Calif., Feb. 7 /PRNewswire/ -- Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the AACR-NCI-EORTC meeting on Molecular Targets and Cancer Therapeutics.
The majority of these agents are novel targeted therapeutics addressing numerous first-in-human targets, in addition to well established markers such as epidermal growth factor receptor (EGFr) and vascular endothelial growth factor receptor (VEGFr) tyrosine kinases. Among these novel drugs are various multitargeted agents and those blocking such targets as Aurora, polo-like kinase I (plk1), transferrin, stromal-derived factor 1 (SDF-1), insulin-like growth factor-1 (IGF-1), Met, nucleolin, mitogen-activated protein kinase (MAPK)/ERK (MEK), telomerase, etc.
Depending on the results of these trials, many of these agents will proceed to phase II monotherapy clinical trials, as well as phase I trials in combinations with standard approved chemotherapeutics and/or other novel targeted drugs.
The list of agents in monotherapy phase I trials and their targets has been posted on the subscriber menu page of nm|OK. A detailed description of these agents has also been published in New Medicine's analytical newsletter, Future Oncology. Currently in its 10th year, Future Oncology has covered every aspect of the oncology field, and represents a powerful resource for professionals involved in the development or marketing of products in this sector. A sample issue of Future Oncology, as well as indices and tables of contents of previous issues may be found at http://newmedinc.com/.
New Medicine's Oncology KnowledgeBASE (nm|OK), residing at http://www.nmok.net/, is an edited, inclusive analysis of all aspects of the oncology field relating to products, technologies, targets, companies, business affiliations, medical and clinical developments, including protocols and results of thousands of clinical trials, and global markets, among others. For additional information or to sign up for a no-obligation demonstration of the database and a temporary 7-day pass, please contact:
Katie Siafaca Editor and Publisher Oncology KnowledgeBASE (nm|OK) e-mail: info@newmedinc.com Tel: (949) 830-0448 FAX: (949) 830-0887 http://nmok.net/ http://newmedinc.com/New Medicine
CONTACT: Katie Siafaca, Editor and Publisher, Oncology KnowledgeBASE(nm|OK), +1-949-830-0448, fax +1-949-830-0887, info@newmedinc.com
Web site: http://nmok.net/
Web site: http://newmedinc.com/
Source: PRNewswire
Related Articles
- Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
- Elan and Transition Achieve Enrollment Target in Phase II Alzheimer's Study
- Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
- The GI Company Reports Additional Phase II Clinical Data of Intestinal Trefoil Factor (rhITF) Oral Spray for Oral Mucositis
- Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
- Vion Pharmaceuticals Presents Updated Clinical Data From a Phase II Trial of Cloretazine(R) (VNP40101M) in Patients With Relapsed or Refractory Small Cell Lung Cancer
- Anesiva Announces Clinical Data From Phase 1 Trial of 1207
- Oncology Drug Development Update - Targeting the Epidermal Growth Factor Receptor (EGFr) Signal Transduction Pathway
- Interim Data From Targeted Genetics' Phase I HIV/AIDS Vaccine Trial
- New Cancer Center Clinic Targets High-Risk Women
 |
 |
User Comments (0)
RSS Feeds